A pathological contribution by MAO-A in AD is further suggested by the accumulation of toxic metabolites of MAO-mediated deamination in AD patients [66] as well as by the ability of MAO-A inhibition to reduce the ROS production associated with treatment of HT-22 cells with the AD-related Aβ(1–40) peptide (present study). Here, MAOA is linked to Alzheimer disease.